Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing…
